{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.7","upperLimit":"40.5","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"}],"units":"Participants"}],"description":"Complete Remission was defined by the following criteria:\n\n* bone marrow blasts ≤ 5%\n* no evidence of disease\n* full recovery of peripheral blood counts:\n\n  * platelets \\> 100,000/μL, and\n  * absolute neutrophil count (ANC) \\> 1,000/μL","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Primary analysis set","reportingStatus":"POSTED","timeFrame":"Within the first 2 cycles of treatment, 12 weeks","title":"Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}